Divi's Laboratories Limited

BSE: 532488 NSE: DIVISLAB
Divi's Laboratories Limited - pharma in Hyderabad, Telangana, India. FY 2026 financials & compliance.
CIN L24110TG1990PLC011854 Incorporated 12 October 1990 ROC Hyderabad HQ Hyderabad, Telangana, India
Active Listed - NSE: DIVISLAB · BSE: 532488 Public Limited Company pharma
Data last updated
Market Cap
₹2,55,368 Cr
DIVISLAB · NSE
Share Price
₹9,550.00
-0.72% today
Revenue
₹10,560 Cr
FY 2025-26 · +12.5% YoY
EBITDA
₹3,368 Cr
Margin 31.9%
Net Profit
₹2,623 Cr
FY 2025-26 · +19.7% YoY
P/E (TTM)
85.7x
P/B 15.2x
ROE
16.2%
ROCE 21.0%
Debt / Equity
0.00
Interest cover 0.8x

About Divi's Laboratories Limited

Data last updated: 28 September 2026

Divi's Laboratories Limited is a public limited company based in Hyderabad, Telangana, India. It specialises in api manufacturers, a part of the broader pharmaceuticals sector. Incorporated on 12 October 1990, the company has been in operation for over 36 years.

Registered with ROC Hyderabad under CIN L24110TG1990PLC011854. Listed on BSE: 532488 and NSE: DIVISLAB.

Capital: an authorised share capital of ₹60 Cr and a paid-up capital of ₹53.09 Cr. Formerly known as Divi'S Research Centre Private Limited and Divi'S Laboratories Private Limited. It is led by directors including Nimmagadda Venkata Ramana and Murali Krishna Prasad Divi.

Last AGM: 10 August 2026. Financial statements filed for year ended 31 March 2026. Office: 1 – 72/23(P)/Divis/303 Divi Towers Cyber Hills Gachibowli, Hyderabad, Telangana, India – 500032.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹10,560 Cr, a growth of 12.82% compared to the previous year. The net worth stands at ₹16,761 Cr (up 11.97% YoY). Total assets are valued at ₹17,523 Cr (up 17.03% YoY).

The company has a workforce of approximately 11,560 employees as per the latest available data.

The company is associated with 2 brands - Divis Nutraceuticals, Divis Laboratories. As per MCA filings, the company has open charges of ₹515 Cr and satisfied charges of ₹1,186.72 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website divislabs.com.

Company Details of Divi's Laboratories Limited
CIN L24110TG1990PLC011854
Registration Number 011854
Incorporation Date 12 October 1990
ROC Hyderabad
Listing Status Listed (BSE: 532488, NSE: DIVISLAB)
Company Status Active
Date of Last AGM 10 August 2026
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant
Key People
Murali Krishna Prasad Divi Managing Director Nimmagadda Venkata Ramana Whole-Time Director Motaparti Nilima Whole-Time Director
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    divislabs.com
  • Social Media
  • Registered Address
    1 – 72/23(P)/Divis/303 Divi Towers Cyber Hills Gachibowli, Hyderabad, Telangana, India – 500032
  • Industry
    Pharma, API Manufacturers
Company report
Divi's Laboratories Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Divi's Laboratories Limited report

Financials, compliance, directors, charges, ownership and filings for Divi's Laboratories Limited in one report.

10-year financials Directors & ownership Charges & compliance

Name History of Divi's Laboratories Limited

Divi's Laboratories Limited has undergone 2 name changes throughout its history. The company was previously known as Divi's Research Centre Private Limited, and Divi's Laboratories Private Limited. The current legal name is Divi'S Laboratories Limited, reflecting the company's evolution and rebranding over time.

Company Name Status
Divi's Laboratories Limited Current
Divi's Research Centre Private Limited Previous
Divi's Laboratories Private Limited Previous

CIN History of Divi's Laboratories Limited

Divi's Laboratories Limited has one previous CIN (Corporate Identification Number): L24110AP1990PLC011854. The current CIN is L24110TG1990PLC011854, which is the unique identifier assigned by the Registrar of Companies.

CIN Status
L24110TG1990PLC011854 Current
L24110AP1990PLC011854 Previous

Associated Brands with Divi's Laboratories Limited

Divi's Laboratories Limited operates two associated brands: Divis Nutraceuticals and Divis Laboratories. These brands represent Divi's Laboratories Limited's diversified market presence and brand portfolio.

Brand Description Website
Divis Nutraceuticals
Manufacture of carotenoid and vitamin ingredients for food, beverage, and nutrition industries. divisnutraceuticals.com
Divis Laboratories
Contract manufacturer of APIs, intermediates, and building blocks of peptides and nucleotides divislabs.com

Competitors & Alternatives of Divi's Laboratories Limited

Brands and companies operating in the same space as Divi's Laboratories Limited include Laurus Labs, Symbiotec, NGL Fine Chem and 5 more.

Competitor Description Location Founded
Laurus Labs Laurus Labs Pharmaceutical and biotechnology company Hyderabad, India, India 2005
Symbiotec Symbiotec Non-sterile steroid hormone-based APIs and intermediates are manufactured. Indore, India, India 2002
NGL Fine Chem NGL Fine Chem CDMO specializing in multi stage organic synthesis of generic APIs and fine chemicals Mumbai, India, India 1981
Beijing Biostar Technologies Beijing Biostar Technologies APIs, intermediates, and biochemical reagents are developed and manufactured. Beijing, China, China 2002
Sterling Pharma Solutions Sterling Pharma Solutions Contract development, manufacturing, and analytical services for APIs are offered. Dudley, United Kingdom, United Kingdom 2016
Provepharm Life Solutions Provepharm Life Solutions APIs and drug products are developed and valorized in pharmaceuticals. Marseille, France, France 1998
Snapdragon Chemistry Snapdragon Chemistry Drug discovery and development service provider Cambridge, United States, United States 2014
SeQuent SeQuent APIs are developed and manufactured for therapeutic areas. Bengaluru, India, India 2002

Business Activity of Divi's Laboratories Limited

Divi's Laboratories Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products Locked
Premium access

Business activity turnover details for Divi's Laboratories Limited

Turnover contribution percentages and historical activity changes require an active report plan.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Verified entity values are shown only after access is granted.

Auditor Details of Divi's Laboratories Limited

Divi's Laboratories Limited is audited by Price Waterhouse Chartered Accountants LLP for the financial year 2023. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.

Name Status Appointment Date Cessation Date
Price Waterhouse Chartered Accountants LLP Locked Locked Locked
Premium access

Complete auditor history for Divi's Laboratories Limited

Appointment status, appointment dates, cessation dates, and historical auditor changes require an active report plan.

  • Appointment status
  • Appointment dates
  • Cessation dates
  • Auditor changes

Verified entity values are shown only after access is granted.

Board of Directors of Divi's Laboratories Limited

Divi's Laboratories Limited is currently managed by 10 directors, with 12 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Nimmagadda Venkata Ramana
Also directs: Maarrc Padmini Real Yield Llp
Whole-Time Director 01 Oct 1994 31 Years 11 Months Current
Murali Krishna Prasad Divi
Also directs: Divi's Biotech Private Limited, Divi's Properties Private Limited, Divi's Resorts And Agro Farms Private Limited
Managing Director 12 Oct 1990 35 Years 11 Months Current
Ganapaty Seru Director 22 Jul 2017 9 Years 2 Months Current
Sunaina Singh Director 28 Mar 2019 7 Years 6 Months Current
Rajendra Kumar Premchand
Also directs: Brs Medical Llp, Rksn Food & Beverages Private Limited, Indo-Asian Cardiac Research Centre Private Limited and 2 more
Director 25 May 2024 2 Years 4 Months Current
Motaparti Nilima
Also directs: Divi's Biotech Private Limited, Divi's Properties Private Limited, Divi's Resorts And Agro Farms Private Limited and 3 more
Whole-Time Director 27 Jun 2017 9 Years 3 Months Current
Showing 6 of 10 current directors. View all directors

Financials of Divi's Laboratories Limited FY 2025-26 filings available

Divi's Laboratories Limited reported revenue of ₹10,560 Cr (up 12.82% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹10,560 Cr
+12.8% YoY
EBITDA
₹3,368 Cr
+13.4% YoY
Profit After Tax
₹2,623 Cr
+19.7% YoY
Net Worth
₹16,761 Cr
+12.0% YoY
Total Assets
₹17,523 Cr
+17.0% YoY
Total Debt
₹7.00 Cr
+75.0% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue10,5609,3607,8457,7688,9606,9695,394
Revenue growth+12.5%+13.3%+4.5%+6.3%+23.6%+15.0%+16.2%
EBITDA3,3682,9692,2062,3693,8832,8611,823
EBITDA margin+31.9%+31.7%+28.1%+30.5%+43.3%+41.1%+33.8%
Profit before tax3,3882,9162,1632,3693,6842,6661,819
Net profit2,6232,1911,6031,8242,9621,9871,335
Net profit margin+24.8%+23.4%+20.4%+23.5%+33.1%+28.5%+24.8%
EPS (₹)96.9182.6860.3868.69111.5374.7551.86
Balance sheet
Total assets17,52314,97313,61112,80111,7599,3257,369
Net worth16,76114,96913,57112,76711,7289,2957,310
Total debt7.004.003.003.263.694.8338.85
Cash & bank3,4143,7153,9804,2132,8192,156123
Net working capital9,0558,6318,3988,2117,1575,0632,816
Cash flow
Cash from operations2,7381,6531,2612,4601,9121,9471,216
Cash from investing(2,219)(804)(269)(2,708)(2,195)75.13(83.47)
Cash from financing(804)(799)(799)(797)(532)(34.89)(1,091)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue3,0802,8312,6042,7152,4102,5852,3192,338
Revenue growth (YoY)+27.8%+9.5%+12.3%+16.1%+13.8%+12.2%+25.0%+22.5%
Other income64.0015588.0014511986.0082.00106
EBITDA1,255934816888729886743716
EBITDA margin+40.7%+33.0%+31.3%+32.7%+30.2%+34.3%+32.0%+30.6%
Depreciation13312011811311210799.0099.00
Interest6.006.006.008.003.001.000.001.00
Profit before tax1,180963780912733864726722
Tax278212197223188202137212
Net profit902751583689545662589510
EPS (₹)33.9528.3121.9825.9720.4924.9322.2019.20
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue10,3889,1987,6657,6258,8806,7995,311
Revenue growth+12.1%+13.3%+4.1%+5.5%+25.8%+13.8%+15.3%
EBITDA3,4152,9802,1752,3493,8782,8221,816
EBITDA margin+32.9%+32.4%+28.4%+30.8%+43.7%+41.5%+34.2%
Profit before tax3,4362,9292,1322,3543,6772,6281,813
Net profit2,6622,2091,5751,8052,9501,9571,331
Net profit margin+25.6%+24.0%+20.6%+23.7%+33.2%+28.8%+25.1%
EPS (₹)98.3883.3659.4768.23111.0873.6451.71
Balance sheet
Total assets17,46614,89713,52112,73611,7189,2977,371
Net worth16,71114,89513,48412,70511,6919,2727,317
Total debt0.002.000.000.000.000.3533.63
Cash & bank3,3713,6963,9614,1882,8042,142107
Net working capital9,0158,5618,3138,1577,1285,0372,821
Cash flow
Cash from operations2,7111,6501,2662,4471,9101,9471,208
Cash from investing(2,218)(803)(268)(2,707)(2,195)75.34(81.38)
Cash from financing(802)(797)(798)(796)(532)(33.97)(1,091)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue2,9742,7932,5782,6602,3572,5362,2972,302
Revenue growth (YoY)+26.2%+10.1%+12.2%+15.6%+14.3%+12.3%+27.1%+23.2%
Other income63.0015487.0014611987.0082.00105
Total expenses1,7341,8501,7451,7651,6141,6551,5501,573
EBITDA1,240943833895743881747729
EBITDA margin+41.7%+33.8%+32.3%+33.6%+31.5%+34.7%+32.5%+31.7%
Depreciation13212011611311210799.0098.00
Interest6.006.006.008.003.000.000.001.00
Profit before tax1,165971798920747861730735
Tax274215200224190194136217

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 28 Sep 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue3,0802,8312,6042,7152,4102,5852,3192,338
Revenue growth (YoY)+27.8%+9.5%+12.3%+16.1%+13.8%+12.2%+25.0%+22.5%
Other income64.0015588.0014511986.0082.00106
EBITDA1,255934816888729886743716
EBITDA margin+40.7%+33.0%+31.3%+32.7%+30.2%+34.3%+32.0%+30.6%
Depreciation13312011811311210799.0099.00
Interest6.006.006.008.003.001.000.001.00
Profit before tax1,180963780912733864726722
Tax278212197223188202137212
Net profit902751583689545662589510
EPS (₹)33.9528.3121.9825.9720.4924.9322.2019.20
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue10,5609,3607,8457,7688,9606,9695,394
Revenue growth+12.5%+13.3%+4.5%+6.3%+23.6%+15.0%+16.2%
Other income50735233934511462.56190
Total expenses7,1926,3915,6395,3985,0774,1083,571
Employee cost1,4421,2431,094975946826621
EBITDA3,3682,9692,2062,3693,8832,8611,823
EBITDA margin+31.9%+31.7%+28.1%+30.5%+43.3%+41.1%+33.8%
Depreciation463402378343312256186
Interest24.003.004.001.962.002.107.14
Profit before tax3,3882,9162,1632,3693,6842,6661,819
Tax820725563545723682443
Net profit2,6232,1911,6031,8242,9621,9871,335
Net profit margin+24.8%+23.4%+20.4%+23.5%+33.1%+28.5%+24.8%
EPS (₹)96.9182.6860.3868.69111.5374.7551.86
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital53.0053.0053.0053.0953.0953.0953.09
Reserves & surplus16,70814,91613,51812,71411,6759,2427,257
Shareholders' funds (net worth)16,76114,96913,57112,76711,7289,2957,310
Minority interest0.000.000.000.000.000.000.00
Secured loans0.002.000.000.000.000.3533.63
Unsecured loans7.002.003.003.263.694.485.22
Total debt7.004.003.003.263.694.8338.85
Total liabilities17,52314,97313,61112,80111,7599,3257,369
Assets
Gross block9,4137,8686,7606,3655,6244,6923,514
Net block6,5285,4424,7394,7234,3253,7042,782
Capital work in progress2,1131,022778212470711920
Investments69.0065.0082.0077.0572.010.01971
Inventories3,9543,2363,1843,0002,8292,1451,864
Sundry debtors2,9842,7312,1561,7932,4241,6771,413
Cash & bank balances3,4143,7153,9804,2132,8192,156123
Loans & advances744399355306280197309
Total current assets11,09610,0819,6759,3128,3526,1753,708
Total current liabilities2,0411,4501,2771,1011,1951,111892
Net working capital9,0558,6318,3988,2117,1575,0632,816
Total assets17,52314,97313,61112,80111,7599,3257,369
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash4133631701,2152,03043.152.10
Net cash from operating activities2,7381,6531,2612,4601,9121,9471,216
Net cash from investing activities(2,219)(804)(269)(2,708)(2,195)75.13(83.47)
Net cash from financing activities(804)(799)(799)(797)(532)(34.89)(1,091)
Net change in cash(285)50.00193(1,045)(816)1,98741.05
Closing cash3,4143,7153,9804,2132,8192,156123
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+12.8%+19.3%+1.0%-13.3%+28.6%+29.2%+9.1%
EBITDA growth+13.4%+34.6%-6.9%-39.0%+35.7%+56.9%-2.7%
PBT growth+16.2%+34.8%-8.7%-35.7%+38.2%+46.5%-1.9%
Net income growth+19.7%+36.7%-12.1%-38.4%+49.1%+48.8%-1.3%
Revenue CAGR (3Y)+10.8%+1.5%+4.0%+12.9%+21.9%+21.4%+9.9%
EBITDA CAGR (3Y)+12.4%-8.6%-8.3%+9.1%+27.5%+31.3%+8.0%
Profitability & leverage
Net income margin+24.3%+23.4%+20.4%+23.5%+33.0%+28.5%+25.5%
Return on capital employed+21.0%+20.4%+16.4%+19.3%+35.0%+32.0%+25.3%
Return on net worth+16.2%+15.4%+12.2%+14.9%+28.2%+23.9%+19.3%
Debt / equity0.000.000.000.000.000.000.01
Long-term debt / equity0.000.000.000.000.000.000.00
Interest cover0.830.120.220.100.060.080.44
Efficiency & per share
Fixed asset turnover1.221.281.201.301.741.701.75
Inventory turnover2.942.922.542.673.603.482.97
Debtors turnover3.703.833.973.684.374.514.19
EPS (₹)96.9182.6860.3868.69111.5374.7551.86
Dividend per share (₹)30.0030.0030.0030.0030.0020.0016.00
Book value per share (₹)632.49564.87512.11480.96441.82350.15275.38
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue2,9742,7932,5782,6602,3572,5362,2972,302
Revenue growth (YoY)+26.2%+10.1%+12.2%+15.6%+14.3%+12.3%+27.1%+23.2%
Other income63.0015487.0014611987.0082.00105
Total expenses1,7341,8501,7451,7651,6141,6551,5501,573
EBITDA1,240943833895743881747729
EBITDA margin+41.7%+33.8%+32.3%+33.6%+31.5%+34.7%+32.5%+31.7%
Depreciation13212011611311210799.0098.00
Interest6.006.006.008.003.000.000.001.00
Profit before tax1,165971798920747861730735
Tax274215200224190194136217
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue10,3889,1987,6657,6258,8806,7995,311
Revenue growth+12.1%+13.3%+4.1%+5.5%+25.8%+13.8%+15.3%
Other income50635233734911162.53190
Total expenses6,9736,2185,4905,2765,0023,9773,494
Employee cost1,4001,2101,067953927809608
EBITDA3,4152,9802,1752,3493,8782,8221,816
EBITDA margin+32.9%+32.4%+28.4%+30.8%+43.7%+41.5%+34.2%
Depreciation461401376342311255186
Interest24.002.004.002.001.731.817.03
Profit before tax3,4362,9292,1322,3543,6772,6281,813
Tax829720556546728673441
Net profit2,6622,2091,5751,8052,9501,9571,331
Net profit margin+25.6%+24.0%+20.6%+23.7%+33.2%+28.8%+25.1%
EPS (₹)98.3883.3659.4768.23111.0873.6451.71
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital53.0053.0053.0053.0053.0953.0953.09
Reserves & surplus16,65814,84213,43112,65211,6389,2187,264
Shareholders' funds (net worth)16,71114,89513,48412,70511,6919,2727,317
Secured loans0.002.000.000.000.000.3533.63
Unsecured loans0.000.000.000.000.000.000.00
Total debt0.002.000.000.000.000.3533.63
Total liabilities17,46614,89713,52112,73611,7189,2977,371
Assets
Gross block9,3977,8596,7526,3585,6184,6853,508
Net block6,5205,4404,7374,7194,3213,6992,776
Capital work in progress2,1131,022778212470711920
Investments76.0072.0089.0084.0079.377.37979
Inventories3,7113,0332,9852,7812,6442,0431,744
Sundry debtors3,2282,8552,2731,9642,5701,7461,533
Cash & bank balances3,3713,6963,9614,1882,8042,142107
Loans & advances724395353303278195305
Total current assets11,0349,9799,5729,2368,2966,1253,690
Total current liabilities2,0191,4181,2591,0791,1681,089869
Net working capital9,0158,5618,3138,1577,1285,0372,821
Total assets17,46614,89713,52112,73611,7189,2977,371
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash3943441441,2002,01627.88(7.96)
Net cash from operating activities2,7111,6501,2662,4471,9101,9471,208
Net cash from investing activities(2,218)(803)(268)(2,707)(2,195)75.34(81.38)
Net cash from financing activities(802)(797)(798)(796)(532)(33.97)(1,091)
Net change in cash(309)50.00200(1,056)(817)1,98835.84
Closing cash3,3713,6963,9614,1882,8042,142107
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+12.9%+20.0%+0.5%-14.1%+30.6%+28.0%+8.8%
EBITDA growth+14.6%+37.0%-7.4%-39.4%+37.4%+55.4%-1.8%
PBT growth+17.3%+37.4%-9.4%-36.0%+39.9%+44.9%-1.1%
Net income growth+20.5%+40.2%-12.7%-38.8%+50.7%+47.0%+1.3%
Revenue CAGR (3Y)+10.9%+1.2%+4.1%+12.8%+22.1%+21.2%+9.7%
EBITDA CAGR (3Y)+13.3%-8.4%-8.3%+9.0%+28.0%+31.1%+8.1%
Profitability & leverage
Net income margin+25.1%+24.0%+20.6%+23.7%+33.2%+28.8%+25.9%
Return on capital employed+21.4%+20.6%+16.3%+19.3%+35.0%+31.6%+25.2%
Return on net worth+16.5%+15.6%+12.0%+14.8%+28.1%+23.6%+19.2%
Debt / equity0.000.000.000.000.000.000.01
Long-term debt / equity0.000.000.000.000.000.000.00
Interest cover0.810.080.220.100.050.070.43
Efficiency & per share
Fixed asset turnover1.201.261.171.271.721.661.73
Inventory turnover3.083.062.662.813.793.593.12
Debtors turnover3.423.593.623.364.124.153.77
EPS (₹)98.3883.3659.4768.23111.0873.6451.71
Dividend per share (₹)30.0030.0030.0030.0030.0020.0016.00
Book value per share (₹)630.60562.08508.83479.43440.44349.28275.63
Want more history and ratios?
You're viewing the latest exchange-filed financials for Divi's Laboratories Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Divi's Laboratories Limited

As per the shareholding pattern for the quarter ended Jun 2026, promoters hold 51.90%, foreign institutional investors hold 20.20%, domestic institutional investors hold 19.40%, retail and other public shareholders hold 8.50% of Divi's Laboratories Limited.

Promoters: 51.90%DII (Domestic Institutional): 19.40%FII (Foreign Institutional): 20.20%Retail & Others: 8.50%
Jun 2026
QUARTER
51.90% Promoters
19.40% DII (Domestic Institutional)
20.20% FII (Foreign Institutional)
8.50% Retail & Others
Promoter holding - history
Now 51.90% · Jun 2026High 51.90% · Sep 2025Low 51.90% · Sep 2025
50%50.8%51.5%52.3%53%Sep 2025Dec 2025Mar 2026Jun 2026Sep 2025: 51.90%Dec 2025: 51.90%Mar 2026: 51.90%Jun 2026: 51.90%51.90%51.90%
Shareholding trend - last 6 quarters
Jun 2026Mar 2026Dec 2025Sep 2025
Promoters51.90%51.90%51.90%51.90%
Public48.10%48.10%48.10%48.10%

Charges & Borrowings of Divi's Laboratories Limited

Open charges
₹515 Cr
Satisfied charges
₹1,186.72 Cr
Breakdown by lending institutions
State Bank of India₹454.50 Cr
State Bank of Hyderabad₹254.84 Cr
Others₹109.50 Cr
State Bank of Hyderabad (Sbh)₹97.74 Cr
Hdfc Bank Limited₹60.50 Cr
Others₹209.64 Cr
Latest charge details
DateLenderAmountStatus
27 Feb 2019 Hdfc Bank Limited ₹60.5 Cr Satisfied
28 Oct 2006 The Bank of Nova Scotia ₹20.9 Cr Satisfied
15 Jun 2006 State Bank of India - Overseas Branch ₹50.58 Cr Satisfied
28 Dec 2005 Bank of Nova Scotia ₹20 Cr Satisfied
06 Oct 2005 State of India ₹27.45 Cr Satisfied

Total charge records: 26 View all charges

Employees and EPFO Compliance at Divi's Laboratories Limited

Divi's Laboratories Limited has a workforce of 11,560 employees as of Sep 10, 2024.

Employee count
11,560
Active EPFO establishments
3
Employee growth
3.88%
Premium access

Employee and EPFO history for Divi's Laboratories Limited

Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

GST Compliance of Divi's Laboratories Limited

Premium access

GST registrations and filing compliance for Divi's Laboratories Limited

State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

Credit Ratings, Litigation & Regulatory Alerts for Divi's Laboratories Limited

Premium access

Credit ratings, litigation, and regulatory alerts for Divi's Laboratories Limited

Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

MSME Payment Delays by Divi's Laboratories Limited

Premium access

MSME payment history for Divi's Laboratories Limited

Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.

  • Outstanding amounts
  • Delay periods and reasons
  • MSME-1 filing history
  • Vendor payment signals

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Divi's Laboratories Limited

Premium access

Corporate group structure for Divi's Laboratories Limited

Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Divi's Laboratories Limited

Premium access

MCA filings and documents for Divi's Laboratories Limited

Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Recent Activity on Divi's Laboratories Limited

Activity
10 Aug 2026
Divi'S Laboratories Limited last Annual general meeting of members was held on 10 Aug 2026 as per latest MCA records.
Activity
31 Mar 2026
Divi'S Laboratories Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Hyderabad.
Charges
07 Feb 2026
A charge registered on 27 Feb 2019 via Charge ID 100246839 with Hdfc Bank Limited was fully satisfied on 07 Feb 2026.
Charges
31 Jan 2026
A charge registered on 14 Dec 1995 via Charge ID 90137808 with State Bank Of India was fully satisfied on 31 Jan 2026.
Directors
25 May 2024
Rajendra Kumar Premchand was appointed as a Director on 25 May 2024 & has been associated with this company since 2 years 4 months.
Directors
10 Feb 2024
Devendra Rao Sureddy was appointed as a Whole-time director on 10 Feb 2024 & has been associated with this company since 2 years 7 months.

Recent News on Divi's Laboratories Limited

Stocks in focus today: 21 April, 2025
21 Apr 2025 · Thehindubusinessline

Frequently Asked Questions about Divi's Laboratories Limited

Divi's Laboratories Limited is an active public limited company in the pharma sector based in Hyderabad, Telangana, India. It was incorporated on 12 October 1990 (36+ years old) and is registered under CIN L24110TG1990PLC011854. Listed on BSE: 532488 and NSE: DIVISLAB. The company has 11,560 employees.

Divi's Laboratories Limited reported revenue of ₹10,560 Cr for FY 2025-26 (up 12.82% YoY) based on consolidated financials.

The current directors of Divi's Laboratories Limited are:

The primary industry of Divi's Laboratories Limited is pharma. The company specifically operates in api manufacturers. The company is currently active in this sector.

Yes. Divi's Laboratories Limited is listed on both BSE (code: 532488) and NSE (symbol: DIVISLAB).

Divi's Laboratories Limited can be reached at the registered office: 1 – 7223PDivis303 Divi Towers Cyber Hills Gachibowli, Hyderabad, Telangana, India – 500032, or through the website divislabs.com.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - compiled from official filings and updated regularly.

Subscription plans available